Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jun;120(12):505-14.
doi: 10.1042/CS20100588.

Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold

Danny J Eckert  1 , Robert L Owens, Geoffrey B Kehlmann, Andrew Wellman, Shilpa Rahangdale, Susie Yim-Yeh, David P White, Atul Malhotra
Affiliations
Clinical Trial

Eszopiclone increases the respiratory arousal threshold and lowers the apnoea/hypopnoea index in obstructive sleep apnoea patients with a low arousal threshold

Danny J Eckert et al. Clin Sci (Lond). 2011 Jun.

Abstract

Recent insights into sleep apnoea pathogenesis reveal that a low respiratory arousal threshold (awaken easily) is important for many patients. As most patients experience stable breathing periods mediated by upper-airway dilator muscle activation via accumulation of respiratory stimuli, premature awakening may prevent respiratory stimuli build up as well as the resulting stabilization of sleep and breathing. The aim of the present physiological study was to determine the effects of a non-benzodiazepine sedative, eszopiclone, on the arousal threshold and the AHI (apnoea/hypopnoea index) in obstructive sleep apnoea patients. We hypothesized that eszopiclone would increase the arousal threshold and lower the AHI in patients with a low arousal threshold (0 to -15 cm H(2)O). Following a baseline overnight polysomnogram with an epiglottic pressure catheter to quantify the arousal threshold, 17 obstructive sleep apnoea patients, without major hypoxaemia [nadir SaO(2) (arterial blood oxygen saturation) >70%], returned on two additional nights and received 3 mg of eszopiclone or placebo immediately prior to each study. Compared with placebo, eszopiclone significantly increased the arousal threshold [-14.0 (-19.9 to -10.9) compared with -18.0 (-22.2 to -15.1) cm H(2)O; P<0.01], and sleep duration, improved sleep quality and lowered the AHI without respiratory event prolongation or worsening hypoxaemia. Among the eight patients identified as having a low arousal threshold, reductions in the AHI occurred invariably and were most pronounced (25±6 compared with 14±4 events/h of sleep; P<0.01). In conclusion, eszopiclone increases the arousal threshold and lowers the AHI in obstructive sleep apnoea patients that do not have marked overnight hypoxaemia. The greatest reductions in the AHI occurred in those with a low arousal threshold. The results of this single night physiological study suggest that certain sedatives may be of therapeutic benefit for a definable subgroup of patients. However, additional treatment strategies are probably required to achieve elimination of apnoea.

PubMed Disclaimer

Figures

Figure 1
Figure 1. A PSG example of the procedure used to quantify the respiratory arousal threshold
PSG tracings are from a baseline study in a 55-year-old female patient with moderately severe obstructive sleep apnoea (AHI = 23 events/h of sleep). EEG, C3–A2; nasal flow, nasal airflow (arbitrary units); Pepi, pressure at the level of the epiglottis. Results presented show an approx. 45-s segment during stage 2 sleep in which the patient is experiencing an approx. 30-s respiratory event. Note the increasing breathing efforts (more pronounced negative Pepi) during the period of impaired airflow up until the point of arousal from sleep (grey-shaded portion of the EEG). As indicated, the respiratory arousal threshold is quantified as the nadir epiglottic pressure during the effort immediately prior to arousal from sleep (in this example approx. −20 cmH2O).
Figure 2
Figure 2. Flow diagram of the enrollment, randomization and analysis procedures
The present study was a double-blind placebo-controlled cross-over study in which an overnight baseline PSG was initially performed to determine eligibility. If deemed eligible, OSA patients were randomized to the allocation order (placebo first or 3 mg of eszopiclone first) and returned for two additional PSG studies at which time the appropriate intervention was administered prior to sleep (visit 1 and visit 2). Refer to the text for further details.
Figure 3
Figure 3. AHI scatter plots representing each individual patient’s AHI during the placebo and eszopiclone condition (n = 17)
Mean ± S.E.M. values are presented adjacent to each condition. *Significant difference compared with placebo.
Figure 4
Figure 4. Stage 2 sleep arousal threshold scatter plots representing each individual patient’s arousal threshold during the placebo and eszopiclone condition (n = 17)
Median (interquartile range) values are presented adjacent to each condition. *Significant difference compared with placebo.
Figure 5
Figure 5. AHI scatter plots during the placebo and eszopiclone condition in (A) the patients with (n = 8) and (B) the patients without (n = 9) a low respiratory arousal threshold (between 0 and −15 cmH2O)
Mean ± S.E.M. values are presented adjacent to each condition. *Significant difference compared with placebo.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med. 1993;328:1230–1235. - PubMed
    1. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med. 2005;353:2034–2041. - PubMed
    1. Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J. The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med. 1999;340:847–851. - PubMed
    1. Kribbs NB, Pack AI, Kline LR, Smith PL, Schwartz AR, Schubert NM, Redline S, Henry JN, Getsy JE, Dinges DF. Objective measurement of patterns of nasal CPAP use by patients with obstructive sleep apnea. Am Rev Respir Dis. 1993;147:887–895. - PubMed
    1. Engleman HM, Wild MR. Improving CPAP use by patients with the sleep apnoea/hypopnoea syndrome (SAHS) Sleep Med Rev. 2003;7:81–99. - PubMed

Publication types

MeSH terms

-